Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp414 | Osteoporosis: treatment | ECTS2013

Treatment with eldecalcitol (ED-71) and raloxifene combined increases cancellous and cortical bone strength in ovariectomized rats

Sakai Sadaoki , Takeda Satoshi , Shiraishi Ayako , Koike Nobuo , Mihara Masahiko , Endo Koichi

Eldecalcitol (ED-71; ELD), a 2β-hydroxypropyloxy derivative of 1α,25(OH)2D3, was approved to treat osteoporosis in Japan in 2011. Raloxifene (RAL), a selective estrogen receptor modulator, is available to treat or prevent postmenopausal osteoporosis. In this study, we compared the effects of combining ELD and RAL against each monotherapy in osteoporotic rats.Eight-month-old female Wistar–Imamichi rats were ovariectomi...